Mutations in the kinase domain of BCR::ABL1 are the most extensively studied mechanism of TKI resistance in CML, but BCR::ABL1-independent mechanisms are involved in some cases. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.